In addition, GRPR antagonists demonstrated in vitro and in vivo antiproliferative effects in several cancer models and the inhibition of tumor growth through different mechanisms, namely by interfering with the epidermal growth factor (EGF) and the vascular endothelial growth factor (VEGF) signaling pathways [14,15,16,17]. Here, VEGFA is linked to cancer.